Showing 6631-6640 of 9121 results for "".
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- Psoriasis Pipeline: What's Here and What's Coming in Orals, Biologics, and Beyondhttps://practicaldermatology.com/news/psoriasis-pipeline-orals-biologics-and-beyond/2471551/
- Exosomes for Hair Regrowth: Tech with Potentialhttps://practicaldermatology.com/news/exosomes-for-hair-regrowth-tech-with-potential/2471533/
- AI Highlighted as Potential Game-Changer for GPP, HShttps://practicaldermatology.com/news/AI-Highlighted-Potential-Game-Changer-GPP-HS/2471522/Diagnosing and efficiently treating rare diseases in dermatology has long been an important challenge, and one session at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlighted how artificial intelligence (AI) can help. “Using Artificial Intelligence for Rare Dermatolog
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://practicaldermatology.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.
- Analysis: AI Sensor Reduces Scratching in Atopic Dermatitis Patientshttps://practicaldermatology.com/news/ai-sensor-reduces-scratching-in-atopic-dermatitis/2471104/A wearable sensor utilizing artificial intelligence (AI) with haptic feedback significantly reduced nocturnal scratching in adults with mild atopic dermatitis, a new study reports. Researchers for the single-arm, two-stage cohort study recruited 10 adults (60% female; mean age, 36) with at
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Dermavant Receives Approval of Tapinarof for Psoriasis and Atopic Dermatitis in Japanhttps://practicaldermatology.com/news/dermavant-receives-approval-tapinarof-psoriasis-and-atopic-dermatitis-japan/2467170/Dermavant Sciences announced that Japan Tobacco has received approval in Japan for tapinarof c